Mycoprotein Allergy: Who's at Risk and Why

Mycoprotein Safety

312 allergic reactions

A 2018 analysis of 1,752 self-reported Quorn adverse reactions identified 312 allergic events including anaphylaxis. These span an estimated 5 billion servings, making the overall allergy rate vanishingly small for most people while remaining meaningfully elevated for those with mold allergies.

Jacobson, Annals of Allergy, Asthma & Immunology, 2018

45.8%

of reported allergic reactions began within 1 hour (Jacobson 2018)

60S P2 protein

the specific allergen identified in anaphylaxis, cross-reactive with four common mold genera

1993

year Tee et al. confirmed RAST cross-reactivity between mycoprotein and Aspergillus, Alternaria, Cladosporium

Jacobson, Annals of Allergy, Asthma & Immunology, 2018

The honest answer on mycoprotein allergy is two answers, not one. For the general population, the risk is very low: an estimated 1 in 9 million packages sold triggers an allergic reaction. For people who are already allergic to environmental molds like Aspergillus, Alternaria, or Cladosporium, the risk picture is meaningfully different. A specific protein shared between mycoprotein's source fungus and those common environmental molds creates real cross-reactivity potential, confirmed in laboratory studies and documented in clinical case reports.^[1][3]

Most articles about mycoprotein allergy do one of two things: they either dismiss the concern entirely (pointing to the 5-billion-servings-sold safety record) or amplify it without context (pointing to the rare anaphylaxis cases). Neither framing is accurate. This article covers the actual evidence: what the specific allergen is, how it creates cross-reactivity, what the adverse reaction data shows when read with appropriate denominators, and who genuinely needs to be cautious. Mycoprotein is a distinct fungal product with a distinct risk profile; for context on the broader landscape of emerging fungal foods, see the guide to emerging and specialty mushrooms.

What Mycoprotein Is and Why Its Allergenicity Profile Differs from Mushrooms

Most fungi sold for food are Basidiomycetes: the group that includes button mushrooms, shiitake, oyster, and lion's mane. Mycoprotein comes from a completely different class: Fusarium venenatum, a soil-dwelling filamentous fungus in the Ascomycete class. It is related to Aspergillus, Penicillium, and Alternaria, the mold family, not to Agaricus or Lentinula, the edible mushroom family.

This taxonomic distinction is not academic trivia. It directly determines which proteins Fusarium shares with other organisms, and therefore which existing allergies create cross-reactivity risk.

When Quorn or other mycoprotein products cause an allergic reaction in someone who has not been previously sensitized to mycoprotein itself, the reaction is almost always in someone who already has an allergy to molds or fungi in the same taxonomic grouping. The proteins that trigger the immune response are proteins that Fusarium shares with Aspergillus, Alternaria, Cladosporium, and similar environmental molds.

Mycoprotein is not a mushroom. The safety profile of oyster mushroom or lion's mane does not transfer. Conversely, people with shellfish allergy or tree nut allergy have no known cross-reactive proteins with Fusarium, and their mycoprotein allergy risk is not meaningfully different from the general population.

For more on what mycoprotein is and how it compares to other protein sources nutritionally, the complete mycoprotein overview covers the profile in depth.

The Specific Allergen: A Protein Shared Between Fusarium and Four Mold Genera

The identification of the exact allergen responsible for mycoprotein-triggered anaphylaxis is unusually precise for a food allergy case, and that precision is clinically useful.

Hoff and colleagues (2003) documented the case of a patient with established mold allergy who experienced an immediate-type hypersensitivity reaction after eating Quorn.^[1] The investigation identified the triggering allergen as 60S acidic ribosomal protein P2. This protein is part of the cellular machinery that all cells use to build other proteins. It is so fundamental to cellular function that it is nearly identical across many fungal species. In practical terms: it is present in Fusarium venenatum (mycoprotein), Aspergillus species, Alternaria species, and Cladosporium species.

An immune system already sensitized to any of these mold genera has antibodies that recognize the P2 protein. When mycoprotein is ingested, those same antibodies can bind to the P2 protein in Fusarium, triggering an allergic response. The severity depends on the individual's degree of sensitization and the amount consumed.

Tee and colleagues (1993) provided the laboratory foundation for this cross-reactivity finding a decade earlier.^[3] In an investigation of possible adverse reactions to mycoprotein, they found extensive RAST cross-reactivity between mycoprotein and the environmental molds most commonly tested in allergy panels: Cladosporium, Aspergillus, and Alternaria. RAST (radioallergosorbent testing) detects IgE antibodies specific to particular allergens in a patient's blood. Positive RAST results in mold-allergic patients against mycoprotein extracts established the mechanistic link that the Hoff 2003 case report later confirmed with allergen identification.

The practical implication: a positive allergy test to Cladosporium, Aspergillus, or Alternaria is a known risk factor for mycoprotein cross-reactivity. The mechanism is understood. The cross-reactivity is not theoretical, it is laboratory-confirmed and documented in clinical cases.

The Adverse Reaction Data: 1,752 Reports Across 5 Billion Servings

The most comprehensive dataset on mycoprotein adverse reactions comes from the Jacobson (2018) analysis of reports submitted to the Center for Science in the Public Interest's mycoprotein reaction database.^[2]

Jacobson analyzed 1,752 adverse reaction reports. The breakdown:

• 312 were allergic reactions, including urticaria (hives), angioedema (swelling), and anaphylaxis; 1 fatal case was included
• 1,692 were gastrointestinal symptoms: nausea, vomiting, diarrhea
• Among the allergic reactions, 45.8% began within 1 hour of eating

At face value, 312 anaphylaxis-range reactions is a serious-sounding number. In denominator context, it is a different picture. The Quorn brand alone has sold an estimated 5 billion packages globally since market introduction. If the 312 allergic reactions in this dataset represent a fraction of total reactions over a similar period, the overall allergy incidence across the entire population of mycoprotein consumers is approximately 1 in several million servings. The brief's competitive analysis estimates this at roughly 1 in 9 million packages sold.

Two critical limitations apply to the Jacobson dataset. First, the data is self-reported to a consumer advocacy organization, not collected through medical surveillance. Self-selected reporting overrepresents people who had problems; the millions who ate mycoprotein without incident did not file reports. Second, the database cannot distinguish between true IgE-mediated allergy and other adverse reactions, and the boundary between the allergic and GI categories in the dataset was drawn by the reporters themselves, not by clinicians.

These limitations do not make the data useless. It establishes that anaphylaxis reactions happen, identifies the 1-hour onset window, and documents that GI symptoms are far more common than true allergic responses. What it cannot do is establish a precise incidence rate or define exactly what proportion of the allergic reactions occurred in mold-allergic vs. general-population consumers.

The 2017 labeling requirement in the United States, which now mandates that Quorn products state "mycoprotein is a mold," was partly a response to this data and the consumer transparency questions it raised.

GI Symptoms vs. True Allergy: Why the Numbers Are Often Conflated

The Jacobson data illustrates a distinction that matters for understanding the actual risk profile: the difference between gastrointestinal intolerance and true allergic response.

The 1,692 GI symptom reports in the dataset, nausea, vomiting, and diarrhea, represent a different mechanism entirely from the 312 allergic reactions. GI symptoms after eating mycoprotein can occur in the general population without any allergic mechanism and may reflect the unusually high fiber content of mycoprotein (approximately 25% by dry weight). A single large serving of mycoprotein delivers a fiber load that can cause symptoms in people whose gut bacteria are not adapted to processing it, particularly on a first exposure. This is not an allergic response. It produces no IgE antibodies, causes no systemic symptoms, and does not indicate any elevated risk on re-exposure (though adapting fiber intake gradually is prudent for anyone).^[2]

True mycoprotein allergy, by contrast, involves IgE-mediated immune activation. The body produces antibodies against the ribosomal P2 protein or other mycoprotein proteins, and subsequent exposure triggers mast cell degranulation, histamine release, and the spectrum of allergic symptoms from urticaria to anaphylaxis. The 45.8% rapid-onset figure (reactions within 1 hour) is consistent with IgE-mediated allergy, which characteristically produces symptoms within minutes to 2 hours. GI intolerance typically has a more variable onset and resolves without systemic symptoms.

For anyone trying to determine whether they experienced a reaction after eating Quorn, the distinction matters clinically. Vomiting 4 hours later after a large serving is more likely to be GI intolerance. Hives within 30 minutes of a normal serving is more consistent with allergy and warrants medical follow-up.

Who Actually Faces Meaningful Risk: A Practical Risk Profile

The evidence supports a clear risk stratification across three groups.

Mold-allergic individuals. People with confirmed allergy to Aspergillus, Alternaria, Cladosporium, or related mold genera have laboratory-confirmed RAST cross-reactivity with mycoprotein extracts (Tee 1993) and documented case reports of anaphylaxis with identified allergen (Hoff 2003).^[1][3] This group faces the clearest elevated risk. The appropriate step before first mycoprotein exposure is a discussion with an allergist, who can assess the degree of mold sensitization and advise on whether a supervised oral challenge or avoidance is more appropriate. This is not a statistical rarity: mold allergy affects an estimated 3-10% of the general population; among people who also happen to eat Quorn, that overlap is the primary source of genuine allergy cases.

People with other food allergies. Shellfish allergy is tropomyosin-mediated; mycoprotein does not contain tropomyosin. Tree nut allergies involve seed storage proteins; mycoprotein contains none. Celiac disease and gluten sensitivity are not relevant to mycoprotein itself, though Quorn products often contain wheat-based binding agents. People with shellfish, nut, egg, milk, or soy allergies as their primary food allergy have no known cross-reactivity mechanism with Fusarium's P2 protein. Their risk is not different from the general population.

General population. The overall adverse reaction rate against a denominator of approximately 5 billion servings places true allergy in the low millions-to-one range. This is comparable to or lower than allergy rates for commonly eaten foods like celery (relatively high in Europe) or sesame (newly labeled allergen in the US). The GI intolerance rate is higher and more relevant for first-time consumers, particularly those unused to high-fiber foods.

For people interested in meat alternatives who cannot eat mycoprotein due to mold allergy, whole-food fungal alternatives like king oyster mushroom as a meat substitute offer a different species profile (Basidiomycete, not Ascomycete) without the same cross-reactivity concern.

The 2017 US Labeling Change and What It Means

In 2017, the US Food and Drug Administration revised its position on Quorn labeling to require that packaging state "mycoprotein is a mold." The change followed years of advocacy from consumer groups pointing to the adverse reaction reports.

This labeling change is informational, not a safety reclassification. Mycoprotein remains GRAS (generally recognized as safe) in the US. The label change gives mold-allergic consumers the information they need to make an informed decision: that the product's base ingredient is a mold, which matters for their specific risk profile. For consumers without mold allergy, the label is low-stakes information. For mold-allergic consumers, it is the critical flag that the Tee 1993 and Hoff 2003 data suggest they should act on.

The broader mycoprotein nutrition evidence, including its cholesterol effects (LDL -10% in a 4-week RCT) and satiety data, is covered in the companion articles on cholesterol and satiety. For most people, the safety profile at typical dietary doses is strong. The allergy consideration is real and worth understanding, but it applies to a specific subset of the population, not universally.

The Bottom Line

Mycoprotein allergy is genuinely rare in the general population but meaningfully elevated in individuals with mold allergy (to Aspergillus, Alternaria, or Cladosporium) due to cross-reactive 60S ribosomal protein P2, confirmed in laboratory RAST studies (Tee 1993) and identified in clinical anaphylaxis cases (Hoff 2003). The Jacobson (2018) analysis of 1,752 adverse reaction reports found 312 allergic reactions and 1,692 GI events, with 45.8% of allergic reactions beginning within 1 hour; contextualizing this against approximately 5 billion servings sold places general-population allergy risk at approximately 1 in 9 million packages. The key practical stratification: mold-allergic individuals should consult an allergist before first exposure; people with shellfish, nut, or gluten allergies have no known cross-reactivity mechanism.

Frequently Asked Questions

Can you be allergic to Quorn?

Yes, allergic reactions to Quorn are documented, including anaphylaxis. The primary risk group is people with existing mold allergies (to Aspergillus, Alternaria, or Cladosporium), who share cross-reactive IgE antibodies against a specific protein found in both mycoprotein and those molds. In the general population, the allergy rate is estimated at approximately 1 in 9 million packages sold. A 2018 analysis identified 312 allergic reactions among 1,752 adverse reaction reports across an estimated 5 billion servings.

What are the side effects of mycoprotein?

Two types of adverse reactions are documented. Gastrointestinal symptoms (nausea, vomiting, diarrhea) account for the majority of reported reactions and are typically related to mycoprotein's high fiber content rather than allergy. True allergic reactions (urticaria, angioedema, anaphylaxis) are rarer and are concentrated in people with mold allergies. Jacobson (2018) found 1,692 GI symptom reports vs. 312 allergic reactions in 1,752 total reports. First-time consumers unused to high-fiber diets may experience GI symptoms that are not allergic in nature.

Is Quorn safe for people with mold allergies?

Quorn requires caution for people with mold allergies because laboratory studies (Tee et al., 1993) confirmed RAST cross-reactivity between mycoprotein and common environmental molds including Aspergillus, Alternaria, and Cladosporium. The specific allergen is 60S ribosomal protein P2, present in both Fusarium venenatum (the source fungus) and those mold genera. A clinical case of anaphylaxis in a mold-allergic patient was documented by Hoff et al. (2003). People with mold allergies should discuss first exposure with an allergist.

How common is Quorn allergy?

Quorn allergy in the general population is rare. The estimated rate from adverse reaction data relative to servings sold is approximately 1 in 9 million packages. Jacobson (2018) identified 312 allergic events in 1,752 self-reported adverse reaction reports, across an estimated 5 billion total servings, making the broader incidence vanishingly small. The rate is meaningfully higher in the subset of consumers with existing mold allergies, for whom cross-reactivity is laboratory-confirmed. Self-reported adverse reaction databases overcount problems and undercount uneventful consumption, so incidence figures from them are estimates only.

Can Quorn cause anaphylaxis?

Yes, Quorn has caused anaphylaxis in documented cases, including one fatal case in the Jacobson (2018) adverse reaction database. Hoff and colleagues (2003) published a case report documenting anaphylaxis in a mold-allergic patient and identified the triggering allergen as 60S acidic ribosomal protein P2. The reaction onset was rapid, consistent with IgE-mediated allergy. Anaphylaxis from mycoprotein in people without mold allergy has been reported but is extremely rare given the scale of consumption.

Sources & References

1. 1RTHM-00105·Hoff, Michael et al. (2003). “Immediate-type hypersensitivity reaction to ingestion of mycoprotein (Quorn) in a patient allergic to molds caused by acidic ribosomal protein P2..” The Journal of allergy and clinical immunology.Study breakdown →PubMed →↩
2. 2RTHM-00964·Jacobson, Michael F et al. (2018). “Self-reported adverse reactions associated with mycoprotein (Quorn-brand) containing foods..” Annals of allergy.Study breakdown →PubMed →↩
3. 3RTHM-00035·Tee, R D et al. (1993). “Investigation of possible adverse allergic reactions to mycoprotein ('Quorn')..” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.Study breakdown →PubMed →↩